Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Vilaprisan in Subjects with Renal Impairment
NCT03411980Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2018
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of vilaprisan in Uterine Fibroids (UF) and endometriosis (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration versus time curve from zero to infinity up to 14 days and Maximum observed drug concentration up to 14 days. Started Feb 2018; status: completed.
02
Drugs
vilaprisan
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT03411980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411980.